SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention as traders discuss a pullback after its prior rally, with technical posts debating whether support will hold or weakness will continue. Some holders view TRX as comparatively resilient and point to its use in stablecoin transfers, while others criticize its price performance and prolonged consolidation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels CAN-2409 prostate-cancer program, with traders watching upcoming clinical data presentations and the planned BLA submission; bullish posters point to the positive Phase 3 results, while skeptics question the regulatory timeline, financing and CEO credibility. The debate is amplified by a sharp share-price decline that some attribute to broader biotech weakness and thin trading, while others see it as company-specific selling pressure.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, led by growth in Dupixent and Eylea HD, has driven a sharp share-price breakout and renewed bullish momentum. Traders are celebrating the new high while watching legacy Eyleas decline and upcoming regulatory decisions as potential counterweights.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative strength versus the tech-heavy Nasdaq, with traders debating whether the rotation can hold or whether weakening momentum will bring a wider selloff. Rising Treasury yields, Fed rate concerns, and Iran-related oil risks recur as bearish macro worries, while others see support for a continued rally.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention as traders debate weakness and rotation in the Magnificent Seven, with some seeing a pullback or support test and others expecting the mega-cap leaders to regain strength. The main bearish concern is whether heavy AI spending can deliver adequate returns, while bullish traders point to the groups resilience and potential to lead a rebound.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as shares slide amid bearish technical calls for a deeper correction and reports of options activity skewed toward puts. Some traders see the weakness as a buying opportunity and remain bullish on gold miners longer term, while others expect further downside as precious metals weaken.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Aetnas weaker 2027 Medicare Advantage star ratings are the main concern, with traders focused on potential pressure to future bonus revenue and margins. The discussion is bearish but divided over whether the setback is already priced in, especially as Humana rallied on stronger ratings.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

ARMs steep selloff and weakening technicals dominate discussion, with traders linking the drop to broader semiconductor weakness and concerns about Intels outlook and AI/CPU demand. Some see the pullback toward support as a buying opportunity, while others warn that high valuation and negative momentum could leave room for further declines ahead of earnings.

Magnite, Inc. provides a technology solution to automate the purchase and sale of digital advertising inventory for buyers and sellers. It features applications and services for digital advertising sellers including websites, mobile applications, and other digital media properties. The company was founded by Frank Addante, Duc Chau, Craig Roah, Julie Mattern and Brian D. Baumgart on April 20, 2007 and is headquartered in New York, NY.

Magnite Inc

Magnites strong quarterly results and raised full-year outlook, particularly continued growth in connected-TV advertising, are driving attention. Traders are broadly positive about the execution, while debating how quickly potential benefits from Google ad-tech remedies could add to growth.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude-oil ETF to position for oil to fall amid volatile Iran and Strait of Hormuz headlines, with speculation about a deal or restored supply competing with fears of further escalation. Many are accumulating shares on expected declines in crude, while others complain that backwardation and daily-reset decay have weakened SCOs performance relative to oil moves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP

Biotech ETFs are riding innovation, obesity drug growth and M&A, offering diversified exposure to the sector???s powerful rally.

Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth 

 Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight

Equity

The company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.


Why Did DAWN Skyrocket Over 65% Pre-Market Today? 

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.


Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth 

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.


IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

ETFis Series Trust I - Virtus Biotech ETF

Neutral Sentiment

<ul class="summary-bullets"><li>ImmunityBio said it removed the referenced podcast from its website and requested removal from external platforms.</li><li>Enhanced compliance measures will include stricter promotional review protocols and mandatory executive-level training.</li><li>ANKTIVA, ImmunityBio’s interleukin-15-based immunotherapy, remains central to the company’s oncology strategy.</li></ul>ImmunityBio Inc. (IBRX) stated on Monday that it has responded to regulatory concerns raised by the U.S. Food and Drug Administration, outlining corrective steps related to promotional content for its cancer therapy as the company seeks to reinforce compliance standards.The company said it submitted a detailed reply to the FDA’s Office of Prescription Drug Promotion following a March 13 communication on marketing materials, including a podcast and a television advertisement.&nbsp;<h2 class="st-heading-2">FDA Inquiry And ImmunityBio’s Response</h2>ImmunityBio clarified that the advertisement in question was never released to the public and addressed issues tied to statements made in the podcast.&nbsp;In response, ImmunityBio removed the referenced podcast from its website and requested its deletion from external platforms hosting the content.&nbsp;<blockquote>“We are dedicated to maintaining a clear distinction between our investigational pipeline aspirations and the promoted indications for our approved therapies.”-Richard Adcock, President and CEO, ImmunityBio</blockquote>&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio stock</a> traded over 3% higher in Monday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Compliance Measures</h2>The Culver City-based firm said it is introducing tighter oversight procedures, including enhanced review protocols for marketing materials, mandatory executive-level compliance training, and the addition of external regulatory advisors to evaluate future communications. These measures are intended to ensure that promotional messaging aligns with FDA standards for accuracy and balance.The podcast in question featured founder Patrick Soon-Shiong, who was discussing long-term scientific ambitions.The company emphasized its commitment to providing clear and compliant information about ANKTIVA, an immunotherapy designed to stimulate key immune cells that target cancer. The treatment builds on the biology of interleukin-15 to enhance the immune response, forming part of ImmunityBio’s broader oncology strategy.IBRX stock has gained over 268% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slno-stock-soars-over-39-what-s-fueling-the-rally/cZJ4SjzRIoU">SLNO Stock Soars Over 39% — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.

ETFis Series Trust I - Virtus LifeSci Biotech Products ETF

ImmunityBio Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$104.18
Prev Close	$105.26
Open	$105.03
Dividend Yield	N/A
50-Day Moving Average	$104.73
Beta	N/A
Avg. Volume	12,941.22
PE Ratio	N/A

52-Week High	$110.05
52-Week Low	$72.81
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

BBP Fundamentals